Starbloom Capital is a venture capital firm investing in breakthrough innovations in deep tech, including longevity biotech, neuroAI, life sciences, and emerging industries. The firm partners with visionary founders pushing the frontiers of science and technology.
40% of their portfolio is in Crypto & Web3. Deal activity increased 200% year-over-year (3 deals in the last 12 months). Average disclosed round size is $15.6M (across 9 rounds with reported amounts).
Portfolio
10
Fund Size
—
Top Stage
Pre Seed
Last 12 Mo
3
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
10 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Adaptyx Biosciences | Seed | $14M | Oct 2025 |
| AAdaptyx Biosciences | Seed | $14M | Oct 2025 |
 Bexorg | Series A | $23M | Oct 2025 |
 0xBow | Seed | $3.5M | Jan 2025 |
| LLIfT Biosciences | Series A | — | Sep 2024 |
 Cognito Therapeutics | Series B | $73M | Mar 2023 |
 Rysk | Pre-Seed | $1.4M | — |
 Sablier | Pre-Seed | $500K | — |
 Elastrin | Unknown | $10M | — |
 Rysk Finance | Pre-Seed | $1.4M | — |
Top Co-Investors
Yunt Capital2 shared
Ascensive Assets2 shared
Lemniscap2 shared
Interlagos2 shared
Cantos2 shared
Overwater Ventures2 shared
Stanford University2 shared
Hyperlink Ventures2 shared
Rev1 Ventures1 shared
Engine Ventures1 shared
Amplify Partners1 shared
Connecticut Innovations1 shared
Balaji Srinivasan1 shared
Boost VC1 shared
Coinbase Ventures1 shared
a16z crypto1 shared
Seaside Equity Partners1 shared
KIZOO Technology Capital1 shared
WS Investment Company1 shared
IAG Capital Partners1 shared
Last updated: 9 September 2026